How to Qualify a CRO in China or India

Global Sites, Local Standards: What Sponsors Must Know Before Outsourcing Nonclinical Studies

As more biotech and pharmaceutical companies expand their nonclinical programs globally, China and India have become key destinations for pharmacology, toxicology, and ADME studies. These regions offer strong scientific capabilities, competitive costs, and expanding GLP infrastructures.

However, qualifying a CRO in Asia requires more than a capability review. Without proper oversight, sponsors risk data integrity issues, misaligned expectations, regulatory delays, and costly repeat studies.

Here’s what every sponsor must evaluate before awarding a study.

1. Verify GLP, Infrastructure & Compliance

A qualified CRO should demonstrate:

• Certified GLP facilities with up-to-date inspection history
• Documented data integrity practices (ALCOA+, audit logs, secure systems)
• Proven experience supporting IND/CTA submissions
• SEND readiness and validated systems

Tip: Ask for recent inspection reports and responses to any findings.

2. Assess Technical Depth & Study-Specific Expertise

Not all CROs excel in every study type. Evaluate their:

• Experience with complex or high-risk studies (e.g., DART, Juvenile, Safety Pharmacology)
• Route-of-administration capabilities (IV, SC, dermal, ocular, inhalation, CNS)
• Analytical and bioanalytical capacity
• Stability, contamination, and product characterization experience

Red flag: “We can run any study you want.”
Great CROs are clear about what they do best.

3. Evaluate Quality Systems & Documentation

Strong documentation is the backbone of regulatory trust. Review:

• SOP structure and version control
• Training records
• Deviations, CAPA management, and incident reporting
• Report writing processes and QC checks
• Controlled templates aligned with ICH standards

Ask to see a sample report, it reveals everything.

4. Examine Data Handling & Digital Compliance

Digital systems must support traceability:

• Secure electronic systems with audit trails
• Raw data structure that aligns with SEND requirements
• Proven workflows for exports and submissions
• Data backup, retention, and cybersecurity

SEND is not optional for FDA-bound programs.

5. Assess Communication, Transparency & Cultural Fit

Successful global studies depend on:

• Clear communication practices
• Defined study timelines
• Weekly or bi-weekly technical meetings
• Rapid escalation paths for protocol deviations or study issues

Compatibility matters as much as capability.

6. Conduct an On-Site or Virtual Qualification Visit

A qualification visit confirms everything on paper:

• Facility tour
• Staff interviews
• Equipment qualification records
• SOP walkthroughs
• Live system demonstrations

Many sponsors skip this step and regret it later.

 How Nikao Lifesciences Helps

Nikao Life Sciences supports biotech, pharma, and medical device companies through:

• CRO identification (US, EU, China, India)
• Qualification visits
• Study placement and contract alignment
• Full monitoring and data QC during execution
• Regulatory-ready reporting and review
• Risk assessment and mitigation planning

Our team ensures you select the right CRO — not just a capable one.

Need Help Choosing or Qualifying a CRO in Asia?

Let Nikao Life Sciences guide your global nonclinical execution with confidence.

Let Nikao Life Sciences guide your global nonclinical execution with confidence.

Email Us: info@nikaolifesci.com
Visit: www.nikaolifesciences.com

Global reach. Local insight. Regulatory confidence.